JP2020522269A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522269A5
JP2020522269A5 JP2019567677A JP2019567677A JP2020522269A5 JP 2020522269 A5 JP2020522269 A5 JP 2020522269A5 JP 2019567677 A JP2019567677 A JP 2019567677A JP 2019567677 A JP2019567677 A JP 2019567677A JP 2020522269 A5 JP2020522269 A5 JP 2020522269A5
Authority
JP
Japan
Prior art keywords
nucleic acid
recombinant nucleic
binding site
mir
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036200 external-priority patent/WO2018226785A1/en
Publication of JP2020522269A publication Critical patent/JP2020522269A/ja
Publication of JP2020522269A5 publication Critical patent/JP2020522269A5/ja
Priority to JP2023135189A priority Critical patent/JP2023164447A/ja
Pending legal-status Critical Current

Links

JP2019567677A 2017-06-06 2018-06-06 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター Pending JP2020522269A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023135189A JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516060P 2017-06-06 2017-06-06
US62/516,060 2017-06-06
PCT/US2018/036200 WO2018226785A1 (en) 2017-06-06 2018-06-06 Self-regulating aav vectors for safe expression of mecp2 in rett syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135189A Division JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Publications (2)

Publication Number Publication Date
JP2020522269A JP2020522269A (ja) 2020-07-30
JP2020522269A5 true JP2020522269A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=64567243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567677A Pending JP2020522269A (ja) 2017-06-06 2018-06-06 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Country Status (15)

Country Link
US (2) US11680275B2 (cg-RX-API-DMAC7.html)
EP (1) EP3635122A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020522269A (cg-RX-API-DMAC7.html)
KR (1) KR20200015701A (cg-RX-API-DMAC7.html)
CN (1) CN111065742A (cg-RX-API-DMAC7.html)
AU (1) AU2018281145A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019025732A2 (cg-RX-API-DMAC7.html)
CA (1) CA3066623A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003582A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019014840A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992882A1 (cg-RX-API-DMAC7.html)
IL (1) IL271170A (cg-RX-API-DMAC7.html)
MX (1) MX2019014760A (cg-RX-API-DMAC7.html)
SG (1) SG11201911737PA (cg-RX-API-DMAC7.html)
WO (1) WO2018226785A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
CN110325219B (zh) * 2016-11-17 2024-03-26 全国儿童医院公司 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
EP3574091B1 (en) 2017-01-30 2023-02-22 Brainvectis Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
EA202092362A1 (ru) 2018-04-03 2021-01-11 Страйдбайо, Инк. Вирусные векторы для нацеливания на ткани глаза
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
AU2019354995B2 (en) 2018-10-02 2024-12-12 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
US20220202960A1 (en) * 2019-04-24 2022-06-30 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
CN114555813A (zh) * 2019-05-21 2022-05-27 国家医疗保健研究所 治疗雷特综合征的胆固醇24-水解酶的表达载体
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
WO2021113634A1 (en) * 2019-12-05 2021-06-10 The Board Of Regents Of The University Of Texas Transgene cassettes designed to express a human mecp2 gene
US12497612B2 (en) 2020-03-09 2025-12-16 University Of Massachusetts Gene replacement therapy for FOXG1 syndrome
PE20230767A1 (es) * 2020-05-13 2023-05-09 Voyager Therapeutics Inc Redireccion del tropismo de las capsides de aav
AU2021300615A1 (en) * 2020-06-30 2023-02-02 The University Court Of The University Of Edinburgh Transgene expression system
US12104163B2 (en) * 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
CN113717248B (zh) * 2020-09-30 2022-07-08 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
IL311861A (en) 2021-11-02 2024-06-01 Voyager Therapeutics Inc Aav capsid variants and uses thereof
GB202201242D0 (en) * 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
CN121219020A (zh) * 2023-03-22 2025-12-26 圣拉斐尔医院有限责任公司 基因疗法
CN121175427A (zh) * 2023-05-15 2025-12-19 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗
TW202513796A (zh) * 2023-06-09 2025-04-01 大陸商仁景(蘇州)生物科技有限公司 表達可調控的工程化rna分子及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
MX346493B (es) 2001-11-13 2017-03-21 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
US20040106566A1 (en) 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
BRPI0817812A2 (pt) 2007-10-23 2015-04-14 Novartis Ag Uso de anticorpos trkb para o tratamento de distúrbios respiratórios
CN102015769B (zh) 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
MX2013004577A (es) 2010-10-25 2014-06-23 Univ Aix Marseille Ii Tratamiento de trastornos asociados a mecp2.
US20160000794A1 (en) 2012-09-25 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods for the diagnosis and treatment of sjogren's syndrome
WO2015038958A1 (en) 2013-09-13 2015-03-19 California Institute Of Technology Selective recovery
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
EP3209311B1 (en) 2014-10-21 2024-03-06 University of Massachusetts Recombinant aav variants and uses thereof
EP3285780A4 (en) 2015-04-24 2018-12-19 University of Massachusetts Modified aav constructions and uses thereof
EP3121284A1 (en) * 2015-07-22 2017-01-25 Ecole Polytechnique Fédérale de Lausanne (EPFL) Bicistronic aav vector for rna interference in als

Similar Documents

Publication Publication Date Title
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2021106619A5 (cg-RX-API-DMAC7.html)
US20220331409A1 (en) Factor ix gene therapy
JP6619454B2 (ja) キャプシド
JP2024009857A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2007507223A5 (cg-RX-API-DMAC7.html)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2018531609A5 (cg-RX-API-DMAC7.html)
TW202005978A (zh) 新穎肝靶向腺相關病毒載體
JP2017509632A5 (cg-RX-API-DMAC7.html)
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2020519284A5 (cg-RX-API-DMAC7.html)
JP2020519294A5 (cg-RX-API-DMAC7.html)
FI3177313T3 (fi) Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi
JPWO2021221995A5 (cg-RX-API-DMAC7.html)
JPWO2021222168A5 (cg-RX-API-DMAC7.html)
JP2020533313A5 (cg-RX-API-DMAC7.html)
RU2021132081A (ru) Векторы фактора h и их применения
JPWO2022028472A5 (cg-RX-API-DMAC7.html)
RU2022111695A (ru) Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение
JPWO2021248038A5 (cg-RX-API-DMAC7.html)
JPWO2020210480A5 (cg-RX-API-DMAC7.html)